$-0.07 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO)

October 13, 2018 - By Marie Mckinney

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) LogoInvestors sentiment increased to 2.11 in Q2 2018. Its up 0.87, from 1.24 in 2018Q1. It increased, as 15 investors sold AVEO Pharmaceuticals, Inc. shares while 12 reduced holdings. 32 funds opened positions while 25 raised stakes. 59.55 million shares or 3.24% more from 57.68 million shares in 2018Q1 were reported.
Aqr Cap Management Limited Liability, Connecticut-based fund reported 158,292 shares. Prelude Capital Mngmt Ltd Liability Co has 0% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Perceptive Advsrs Ltd Llc has invested 0.11% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Royal Retail Bank Of Canada reported 8,002 shares. Northern Tru has invested 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Howe And Rusling has invested 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Rhumbline Advisers stated it has 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Winslow Evans And Crocker Inc holds 0% or 446 shares in its portfolio. Ny State Common Retirement Fund invested in 0% or 68,800 shares. Raymond James Svcs Advsrs reported 0% stake. Blackrock has invested 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Vanguard holds 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 4.99M shares. Creative Planning reported 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Millennium Management Limited Liability Company reported 2.51M shares or 0.01% of all its holdings. 19,685 are held by Goldman Sachs Group.

Since May 8, 2018, it had 62 insider buys, and 0 selling transactions for $31.32 million activity. $404,077 worth of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was bought by Florence Anthony A. Jr.. Viswanathan Ravi had bought 70,873 shares worth $151,250. Another trade for 236,479 shares valued at $503,423 was bought by BASKETT FOREST. MAKOWER JOSHUA bought $151,250 worth of stock or 70,873 shares. Another trade for 70,873 shares valued at $151,250 was bought by SANDELL SCOTT D. On Wednesday, May 30 the insider Growth Equity Opportunities IV – LLC bought $591.

Analysts expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report $-0.07 EPS on November, 6.They anticipate $0.05 EPS change or 250.00 % from last quarter’s $-0.02 EPS. After having $-0.15 EPS previously, AVEO Pharmaceuticals, Inc.’s analysts see -53.33 % EPS growth. The stock increased 3.85% or $0.1 during the last trading session, reaching $2.7. About 3.16M shares traded or 23.00% up from the average. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has declined 19.14% since October 13, 2017 and is downtrending. It has underperformed by 34.76% the S&P500.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $423.40 million. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

More notable recent AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) news were published by: Seekingalpha.com which released: “AVEO Pharmaceuticals Enters A Critical Juncture Amid Stock Market Uncertainty. Will Its TKI-That-Could Prevail?” on October 12, 2018, also Nasdaq.com with their article: “Why AVEO Pharmaceuticals Inc. Rocketed Higher Today” published on September 25, 2018, Seekingalpha.com published: “AVEO Pharma continues up move, shares ahead 7%” on September 26, 2018. More interesting news about AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) were released by: Fool.com and their article: “Why AVEO Pharmaceuticals, Inc. Stock Perked Up in September” published on October 10, 2018 as well as Businesswire.com‘s news article titled: “AVEO Oncology to Present Updated Interim Results from the Phase 2 Portion of the TiNivo Study of Tivozanib and …” with publication date: October 09, 2018.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>